A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors,

Olaparib (AZD2281) is an orally active Poly(ADP‐ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. This Phase I dose‐finding study evaluated the tolerability, pharmacokinetics, PAR...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Yamamoto, Noboru, Nokihara, Hiroshi, Yamada, Yasuhide, Goto, Yasushi, Tanioka, Maki, Shibata, Takashi, Yamada, Kazuhiko, Asahina, Hajime, Kawata, Toshio, Shi, Xiaojin, Tamura, Tomohide
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2012
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7713608/
https://ncbi.nlm.nih.gov/pubmed/22145984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2011.02179.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia